Advanced Search
JIANG Hao, ZHOU Tao, GAO Yajie, LIU Jiwei, DONG Yan. Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1223-1226. DOI: 10.3971/j.issn.1000-8578.2014.11.014
Citation: JIANG Hao, ZHOU Tao, GAO Yajie, LIU Jiwei, DONG Yan. Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1223-1226. DOI: 10.3971/j.issn.1000-8578.2014.11.014
shu

Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib

  • Department of Medical Oncology, The First Affiliated Hospital of Dalian Medical University,Dalian 116011,China

More Information
  • Received Date: September 08, 2013
  • Revised Date: November 12, 2013
    Graphical Abstract
    • Abstract
  • Objective To evaluate the efficacy of increasing dose of gefitinib or erlotinib after gefitinib failure in the treatment for advanced non-small cell lung cancer with resistance to routine dose of gefitnib. Methods A total of 40 patients with non-small cell lung cancer with resistance to routine dose of gefitinib after treatment for more than 6 months in The First Affiliated Hospital of Dalian Medical University from June 2007 to May 2012 were enrolled. They were equally randomized into two groups, one group treated with increasing dose of gefitinib, and the other group treated with erlotinib. The clinical efficacy and incidence of adverse reaction were comparatively analyzed. Results The efficacies of increasing dose of gefitinib group and erlotinib after gefitinib failure group were CR 0 vs. 0 case, PR 2 vs. 0 case, SD 11 vs. 13 cases, PD 7 vs. 7 cases. And the median progression free survival (PFS) were 9.1 and 3.0 months, respectively(P<0.05). The most common toxic effects were skin rash and diarrhea. Univariate and multivariate analysis revealed that increasing dose of geftinib or erlotinib after gefitinib failure were the independent prognosis factors. Conclusion Both increasing dose of gefitinib and erlotinib after gefitinib failure can be effective treatments for advanced non-small cell lung cancer to gefitnib responders, but the median PFS was significant prolonged by increasing dose of gefitinib, which appears more informative than replacement therapy with erlotinib in prognosis.
    • FullText(HTML)
    • References (16)
  • [1]
    Kosaka T, Yarabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 20 06, 12(19): 5764-9.
    [2]
    Onitsuka T, Uramoto H, Nose N, et al . Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2): 198-203.
    [3]
    Pao W, Miller VA, Politi KA, et al . Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PloS Med, 2005, 2( 3): e73.
    [4]
    Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall- cell lung cancer dependent on the epidermal growth factor receptor pathway[J]. Clin Lung Cancer, 2009, 10(4): 281-9.
    [5]
    Uramoto H, Iwata T, Onitsuka T, et al. Epithelial-mesenchymaltransition in EGFR-TKI acquired resistant lung adenocarcinoma[J]. Anticancer Res, 2010, 30(7): 2513-7.
    [6]
    Oh IJ, Ban HJ, Kim KS, et al. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase Ⅱ study[J]. Lung Cancer, 2012, 77(1): 121-7.
    [7]
    Li JL, Hao XZ, Wang Y, et al. Clincal response to gefitinib retreatment of lung adenocarcinaoma patients who benefited from an initial gefitinib therapy: a retrospective analysis[J]. Zhongguo Fei Ai Za Zhi, 2012, 15(1): 44-8. [李峻岭, 郝学志, 王燕, 等. 初 始易瑞沙治疗有效的晚期肺腺癌二次使用易瑞沙的疗效分析 [J] 中国肺癌杂志, 2012, 15(1): 44-8.]
    [8]
    Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002, 20(21): 4292-302.
    [9]
    Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies[J]. J Clin Oncol, 2001, 19(13): 3267-79.
    [10]
    Wong AS, Soong R , Seah SB, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer[J]. J Thorac Oncol, 20 08, 3(4): 400-4.
    [11]
    Vasile E, Tibaldi C, Chella A, et al . Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitnib[J]. J Thorac Oncol, 2008, 3(8): 91 2-4.
    [12]
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 20 05, 353(2): 123-32.
    [13]
    Cho BC, Im CK, Park MS ,et al. Phase Ⅱ study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib[J]. J Clin Oncol, 2007, 25(18): 2528-33.
    [14]
    Kaira K，Naito T, Takahashi T, et a1．Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer[J]. Lung Cancer, 2010, 68(1): 99-104.
    [15]
    Yano T，Haro A，Shikada Y, et al. non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features[J]. Int J Clin Oncol, 20 11, 16(4): 287-93.
    [16]
    Hata A, Katakami N, Yoshioka H,et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection[J]. Lung Cancer, 2011, 74(2): 268-73.
    • Related Articles

  • Related Articles

    [1]CHEN Zeng, LIAO Jinrong, SU Ying, HE Zhiyong, HU Dan, LIN Keyu, JIN Shanfeng, LIN Renzhang, LIN Xiandong. Expression of ARL4C in Non-small Cell Lung Cancer and Its Role in EGFR-TKI Resistance[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 498-503. DOI: 10.3971/j.issn.1000-8578.2020.19.1504
    [2]JIANG Yiqian, GUO Qingmin, MO Yongxiang, AN Suhong, XU Jialing, SU Fang, LIU Jian, YU Canbing, XU Xiaoping. Experimental Investigation on Reversing Drug Resistance of Non-small Cell Lung Cancer Stem Cells by Aqueous Extract of Taxus Chinensis[J]. Cancer Research on Prevention and Treatment, 2016, 43(11): 933-936. DOI: 10.3971/j.issn.1000-8578.2016.11.003
    [3]LI Jing, WU Xinhu, LI Bing, WANG Zhen, SHEN Zetian, SUN Ni, ZHU Xixu. Ionizing Radiation Overcomes Gefitinib Resistance of Non-small Cell Lung Cancer Cell Line H1975 in vitro[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1091-1094. DOI: 10.3971/j.issn.1000-8578.2015.11.007
    [4]YE Chao, HE Fei, LI Xiaoyu, CAI Lin. Prognostic Factors for Female Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 771-776. DOI: 10.3971/j.issn.1000-8578.2014.07.018
    [5]HE Zhihui, HONG Tao, SU Qunhao, ZENG Jiangzheng, SANG Shenggang. Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 645-648. DOI: 10.3971/j.issn.1000-8578.2014.06.030
    [6]Liu Mingyue, Hou Guiqin, Gao Tianhui, Cui Yao, Li Xiaoyan, Zhou Yun. Efficacy of Pemetrexed Chemotherapy in Advanced Non-small Cell Lung Cancer with EGFR-TKI Resistence[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 713-715. DOI: 10.3971/j.issn.1000-8578.2012.06.025
    [7]ZHAN Yong-zi, HUANG Chang-jie, HUANG Jian-feng. Clinical Observation of Erlotinib in Treatment of Patients with Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(04): 461-462. DOI: 10.3971/j.issn.1000-8578.2010.04.025
    [8]LI Rui-chao, YU Shi-ying. Clinical Study of Erlotinib as Second / Third Line Therapy in Treatment of Stage ⅢB/Ⅳ Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 325-327. DOI: 10.3971/j.issn.1000-8578.2009.04.018
    [9]LUO Jun-hua, LI Juan. Clinical Experience of Treating Senile Advanced Non-small Cell Lung Cancer by Erlotinib[J]. Cancer Research on Prevention and Treatment, 2009, 36(03): 244-246. DOI: 10.3971/j.issn.1000-8578.2009.03.022
    [10]YAO Wen-xiu, XIE Hua, WEI Yang, ZHOU Hang, YANG Ji-hong, LI Ji-chuan, CAI Xiao-hong, LI Qiang. Forty-two Patients with Advanced Non-small Cell Lung Cancer Were Treated with Gifitinib[J]. Cancer Research on Prevention and Treatment, 2008, 35(03): 204-206. DOI: 10.3971/j.issn.1000-8578.3343

Catalog

    Get Citation
    PDF
    XML
    Article views (1481) PDF downloads (493) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：11641534 Visits today：8883

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return